Colgate-Palmolive or Procter & Gamble: which stock is cheaper in 2026?
As of October 5, 2026, Colgate-Palmolive (CL) trades at 33.4× earnings (P/E) and Procter & Gamble (PG) at 21.9×, according to Kaplio. The median across the 97 consumer staples companies above $2bn in Kaplio's universe is 20.6×. Kaplio's verdict: Colgate-Palmolive, fairly priced; Procter & Gamble, fairly priced. Value range by multiples: $52–$71 for Colgate-Palmolive and $136–$165 for Procter & Gamble. Against its own value range, Procter & Gamble is the cheaper of the two today.
According to the Kaplio Summary
The same verdict as each company's page: price range by multiples, the four lights, the expected return if consensus is right and what Buffett and Lynch would say today.
| Colgate-Palmolive (CL) | Procter & Gamble (PG) | |
|---|---|---|
| Summary valuation | fairly priced ($52–$71) | fairly priced ($136–$165) |
| The four lights | Valuation: P/E 33.4× (fairly priced) Business: ROIC 30 % (excellent) Balance sheet: Net debt/EBITDA 1.7× (solid) Results: 8 of 8 (on track) | Valuation: P/E 21.9× (fairly priced) Business: ROIC 16 % (solid) Balance sheet: Safe zone (solid) Results: 7 of 8 (on track) |
| Expected return (per year) | +23.5 % a year (to 2028) | +8.6 % a year (to 2029) |
| Buffett method | quality 81 · would wait | quality 91 · would wait |
| Lynch method | outside his circle | slow grower · approves |
Metrics side by side
| Metric | Colgate-Palmolive (CL) | Procter & Gamble (PG) |
|---|---|---|
| Overview | ||
| Market Cap | $67.4B | $344B |
| Price | $84.26 | $144.91 |
| Valuation | ||
| P/E | 33.4× | 21.9× |
| P/B | 291× | 6.5× |
| P/S | 3.3× | 4.0× |
| EV/EBITDA | 19.5× | 17.4× |
| FCF Yield | 5.6 % | 4.6 % |
| Dividend Yield | 2.5 % | 3.0 % |
| Profitability | ||
| ROIC | 30.0 % | 16.0 % |
| ROE | — | 29.8 % |
| Gross Margin | 60.4 % | 50.2 % |
| Operating Margin | 20.7 % | 22.7 % |
| Net Margin | 9.7 % | 18.4 % |
| Growth | ||
| Revenue 5Y CAGR | 4.4 % | 2.7 % |
| EPS 5Y CAGR | -3.5 % | 3.5 % |
| FCF 5Y CAGR | 1.9 % | 0.4 % |
| Balance Sheet | ||
| Net Debt / EBITDA | 1.7× | 1.2× |
| Debt / Equity | 33.3× | 0.6× |
Trailing twelve months where available; otherwise the latest fiscal year. Growth: five-year compound annual rate.